Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab

2011291 citationsReviewbronze Open Access

Authors

Toni K. Choueiri · Dana-Farber Cancer Institute

Erica L. Mayer · Dana-Farber Cancer Institute

Youjin Je · Dana-Farber Cancer Institute

Jonathan E. Rosenberg · Dana-Farber Cancer Institute

Paul L. Nguyen · Dana-Farber Cancer Institute

Georges Azzi · Dana-Farber Cancer Institute

Joaquim Bellmunt

Abstract

This is the first comprehensive report to show that bevacizumab is associated with an increased risk of significant heart failure in patients with breast cancer.

Topics & Keywords

Cancer Treatment and Pharmacology Chemotherapy-induced cardiotoxicity and mitigation Peptidase Inhibition and Analysis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 29, Issue 6, pp. 632-638

DOI: 10.1200/jco.2010.31.9129

Field-Weighted Citation Impact: 18.98